StockData
Mirum Pharmaceuticals, Inc. logo

Mirum Pharmaceuticals, Inc. (MIRM) stock

MIRMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30
$92.49+0.54 (+0.59%)

Close on Nov 18, 2026Market cap $6.01BP/E –Yield –

Mirum Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Mirum Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$833.97M. For fiscal 2025 it was -$22.14M. The highest annual figure on record is -$22.14M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$22.14M–
FY2024Dec 31, 2024-$87.61M–
FY2023Dec 31, 2023-$109.15M–
FY2022Dec 31, 2022-$131.22M–
FY2021Dec 31, 2021-$173.41M–
FY2020Dec 31, 2020-$104.30M–
FY2019Dec 31, 2019-$54.74M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$42.54M–
Q1 FY2026Mar 31, 2026-$789.47M–
Q4 FY2025Dec 31, 2025-$4.57M–
Q3 FY2025Sep 30, 2025$2.60M–
Q2 FY2025Jun 30, 2025-$4.99M–
Q1 FY2025Mar 31, 2025-$15.18M–
Q4 FY2024Dec 31, 2024-$24.22M–
Q3 FY2024Sep 30, 2024-$12.68M–
Q2 FY2024Jun 30, 2024-$24.23M–
Q1 FY2024Mar 31, 2024-$26.47M–
Q4 FY2023Dec 31, 2023-$32.59M–
Q3 FY2023Sep 30, 2023-$25.15M–
Q4 FY2022Dec 31, 2022-$34.16M–
Q3 FY2022Sep 30, 2022-$32.88M–
Q2 FY2022Jun 30, 2022-$31.44M–
Q1 FY2022Mar 31, 2022-$32.74M–
Q4 FY2021Dec 31, 2021-$45.58M–
Q3 FY2021Sep 30, 2021-$42.82M–
Q2 FY2021Jun 30, 2021-$37.40M–
Q1 FY2021Mar 31, 2021-$47.61M–
Q4 FY2020Dec 31, 2020-$36.95M–
Q3 FY2020Sep 30, 2020-$21.72M–
Q2 FY2020Jun 30, 2020-$23.60M–
Q1 FY2020Mar 31, 2020-$22.03M–
Q4 FY2019Dec 31, 2019-$18.66M–
Q3 FY2019Sep 30, 2019-$15.87M–
Q2 FY2019Jun 30, 2019-$14.03M–
Q1 FY2019Mar 31, 2019-$6.18M–
Q3 FY2018Sep 30, 2018-$65.00K–

More Mirum Pharmaceuticals figures

See a number that looks wrong?